Targeting angiogenesis in advanced breast cancer

BioDrugs

Volumn 21, Issue 4, 2007, Pages 209-214

  Zelnak, Amelia B ^a   O'Regan, Ruth M ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANASTROZOLE; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERFERON; LETROZOLE; METHOTREXATE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE OVEREXPRESSION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RASH; REVIEW; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 34547113331     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721040-00001     Document Type: Review

References (60)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285 (21): 1182-6
2. Jensen HM, Chen I, DeVault MR, et al. Angiogenesis induced by 'normal' human breast tissue: a probable marker for precancer. Science 1982; 218 (4569): 293-5
3. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977; 195 (4281): 880-2
4. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23 (5): 1011-27
5. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004; 10 (5): 1706-16
6. Epstein M, Ayala R, Tchekmedyian N, et al. HER-2/neu-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF) [abstract]. Breast Cancer Res Treat 2002; 76 Suppl. 1: S143
7. Fuckar D, Dekanic A, Stifter S, et al. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol 2006; 14 (1): 49-55
8. Kaufman B, Scharf O, Arbeit J, et al. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res 2004; 64 (9): 3350-6
9. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001; 93 (4): 309-14
10. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 2001; 19 (16): 3660-8
11. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94 (12): 883-93
12. Guinebretiere JM, Le Monique G, Gavoille A, et al. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J Natl Cancer Inst 1994; 86 (8): 635-6
13. Guidi AJ, Fischer L, Harris JR, et al. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994; 86 (8): 614-9
14. Guidi AJ, Schnitt SJ, Fischer L, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 1997; 80 (10): 1945-53
15. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324 (1): 1-8
16. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84 (24): 1875-87
17. Linderholm BK, Lindahl T, Holmberg L, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001; 61 (5): 2256-60
18. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57 (5): 963-9
19. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997; 89 (2): 139-47
20. Linderholm BK, Lindh B, Beckman L, et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin Breast Cancer 2003; 4 (5): 340-7
21. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61 (14): 5407-14
22. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993; 53 (3): 533-5
23. Gagliardi AR, Hennig B, Collins DC. Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 1996; 16 (3A): 1101-6
24. Haran EF, Maretzek AF, Goldberg I, et al. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 1994; 54 (21): 5511-4
25. Miller KD, Sweeney CJ, Sledge Jr GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19 (4): 1195-206
26. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60 (7): 1878-86
27. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62 (23): 6938-43
28. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002; 8 (1): 221-32
29. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105 (8): R15-24
30. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13 (1): 73-80
31. Burstein HJ, Spigel D, Kindsvogel K, et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study [abstract no. 4]. Breast Cancer Res Treat 2005; 94 Suppl. 1: S6
32. Dana-Farber clinical trials: study ID 05055 [online]. Available from URL: http://www.dana-farber.org/res/clinical/trials/ [Accessed 2007 Jun 21]
33. Ellis GK, Green SJ, Russell CA, et al. SWOG 0012, a randomized phase III comparison of standard doxorubicin (A) and cyclophosphamide (C) followed by weekly paclitaxel (T) versus weekly doxorubicin and daily oral cyclophosphamide plus G-CSF (G) followed by weekly paclitaxel as neoadjuvant therapy for inflammatory and locally advanced breast cancer [abstract no. LBA537]. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24 (Jun 20 Suppl.): 18S
34. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362 (6423): 841-4
35. Borgstrom P, Gold DP, Hillan KJ, et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19 (5B): 4203-14
36. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 (23): 2335-42
37. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349 (5): 427-34
38. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599 [abstract no. LBA4]. Proc Am Soc Clin Oncol 2005; 23 Suppl.: 2s
39. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (5 Suppl. 16): 117-24
40. Ramaswamy B, Rhoades CA, Kendra K, et al. CTEP-sponsored phase II trial of bevacizumab (Avastin) in combination with docetaxel (Taxotere) in metastatic breast cancer [abstract no. 224]. Breast Cancer Res Treat 2003; 82: S50
41. Burstein HJ, Parker L, Savoi J, et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer [abstract no. 446]. Breast Cancer Res Treat 2002; 76: S115
42. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23 (4): 792-9
43. Miller KD, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100) [abstract]. 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 8-11; San Antonio (TX) [online]. Available from URL: http://www.abstracts2view.com/sabcs05/view.php?.nu=SABCS05L_36 [Accessed 2007 May 21]
44. Pegram MD, Yeon C, Ku NC, et al. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 proto-oncogene and vascular endothelial growth factor (VEGF) [abstract no. 3039]. 27th Annual San Antonio Breast Cancer Symposium; 2004 Dec 8-11; San Antonio (TX) [online]. Available from URL: http://www.abstracts2view.com/sabcs/ search.php?query=Pegram [Accessed 2007 Jun 1]
45. ClinicalTrials: NCT00436709 [online]. Available from URL: http://clinicaltrials.gov/ct/show/nct00436709 [Accessed 2007 Jun 21]
46. Motzer RJ, Hutson TE, Tomczak P, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) [abstract no. LBA3]. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24 (18S Jun 20 Suppl.): LBA3
47. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with 'standard of care' therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003; 2 (10): 1011-21
48. Miller KD, Burstein HJ, Elias AD, et al. Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC) [abstract no. 563]. 2005 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2005; 23 (16 Suppl.): 563
49. ClinicalTrials [online]. Available from URL: http://clinicaltrials.gov [Accessed 2007 Jun 21]
50. ClinicalTrials: NCT00270413 [online]. Available from URL: http://clinicaltrials.gov/ct/show/nct00270413 [Accessed 2007 Jun 21]
51. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract no. 4544]. 2005 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2005; 23 (16 Suppl.): 4544
52. Azad NS, Posadas EM, Kwitkowski VE, et al. Increased efficacy and toxicity with combination of anti-VEGF therapy using sorafenib and bevacizumab [abstract no. 3004]. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24 (18 Suppl.): 3004
53. ClinicalTrials: NCT00217399 [online]. Available from URL: http://clinicaltrials.gov/ct/show/nct00217399 [Accessed 2007 Jun 21]
54. ClinicalTrials: NCT00098592 [online]. Available from URL: http://clinicaltrials.gov/ct/show/nct00098592 [Accessed 2007 Jun 21]
55. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000; 60 (17): 4819-24
56. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60 (8): 2178-89
57. ClinicalTrials: NCT00263198 [online]. Available from URL: http://clinicaltrials.gov/ct/show/nct00263198 [Accessed 2007 Jun 21]
58. ClinicalTrials: NCT00216047 [online]. Available from URL: http://clinicaltrials.gov/ct/show/nct00216047 [Accessed 2007 Jun 21]
59. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65 (10): 4389-400
60. ClinicalTrials: NCT00215488 [online]. Available from URL: http://clinicaltrials.gov/ct/show/nct00215488 [Accessed 2007 Jun 21]